CoChat
Sign Up
Cited by 43

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new action mechanisms

Abidi, Parveen, Chen, Wei, Kraemer, Fredric B., Li, Hai, Liu, Jingwen·2006·Journal of Lipid Research
DOI 10.1194/jlr.m600195-jlr200
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.m600195-jlr200

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • LDLR mRNA becomes stabilized two- to three-fold in response to extracellular stimuli including PMA, bile acids, berberine, and TCN.

    “LDLR mRNA has a half-life of approximately 1–2 h in HepG2 cells and it becomes stabilized two- to three-fold in response to extracellular stimuli, including phorbol 12-myristate 13-acetate (PMA) [7], bile acids [8,9], berberine (BBR) [5,10,11], and triciribine (TCN) [12].”

    From Triciribine Engages ZFP36L1 and HuR to Stabilize LDLR mRNA (2020) · cites this paper as [11]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 42

  1. Bays, 2003, Pharmacotherapy for dyslipidemia—current therapies and future agents., Expert Opin. Pharmacother., 4, 1901, 10.1517/14656566.4.11.1901 · DOI
  2. Grundy, 1998, Statin trials and goals of cholesterol-lowering therapy., Circulation., 97, 1436, 10.1161/01.CIR.97.15.1436 · DOI
  3. Ansell, 1999, An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program., J. Am. Med. Assoc., 282, 2051, 10.1001/jama.282.21.2051 · DOI
  4. Brown, 1986, A receptor-mediated pathway for cholesterol homeostasis., Science., 232, 34, 10.1126/science.3513311 · DOI · Paper page
  5. Smith, 1990, Identification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptor gene., J. Biol. Chem., 265, 2306, 10.1016/S0021-9258(19)39976-4 · DOI · Paper page
  6. Briggs, 1993, Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter., J. Biol. Chem., 268, 14490, 10.1016/S0021-9258(19)85265-1 · DOI · Paper page
  7. Wang, 1993, Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. II. Purification and characterization., J. Biol. Chem., 268, 14497, 10.1016/S0021-9258(19)85266-3 · DOI · Paper page
  8. Yokoyama, 1993, SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene., Cell., 75, 187, 10.1016/S0092-8674(05)80095-9 · DOI
  9. Wang, 1994, SREBP-1, a membrane bound transcription factor released by sterol-regulated proteolysis., Cell., 77, 53, 10.1016/0092-8674(94)90234-8 · DOI
  10. Reinoso, 2001, Pharmacokinetic interactions of statins., Methods Find. Exp. Clin. Pharmacol., 23, 541, 10.1358/mf.2001.23.10.677120 · DOI
  11. Nawrocki, 1995, Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor., Arterioscler. Thromb. Vasc. Biol., 15, 678, 10.1161/01.ATV.15.5.678 · DOI
  12. Prueksaritanont, 1999, Metabolic interactions between mibefradil and HMG CoA reductase inhibitors: an in vitro investigation with human liver preparations., Br. J. Pharmacol., 47, 291, 10.1046/j.1365-2125.1999.00903.x · DOI
  13. Barter, 2000, Treating to target with statins., Atheroscler. Suppl., 1, 21, 10.1016/S0021-9150(00)00564-5 · DOI
  14. Williams, 2002, Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors., Clin. Pharmacokinet., 41, 343, 10.2165/00003088-200241050-00003 · DOI
  15. Moghadasian, 2002, A safety look at currently available statins., Expert Opin. Drug Saf., 1, 269, 10.1517/14740338.1.3.269 · DOI
  16. Klotz, 2003, Pharmacological comparison of the statins., Arzneim.-Forsch. Drug Res., 53, 605
  17. Rader, 2001, A new feature on the cholesterol-lowering landscape., Nat. Med., 7, 1282, 10.1038/nm1201-1282 · DOI
  18. Abidi, 2005, ERK-dependent regulation of hepatic LDL receptor expression by herbal medicine berberine., Arterioscler. Thromb. Vasc. Biol., 25, 2170, 10.1161/01.ATV.0000181761.16341.2b · DOI · Paper page
  19. Upton, 2001, Goldenseal root Hydrastis canadensis: standards of analysis, quality control, and therapeutics., American Herbal Pharmacopoeia and Therapeutic Compendium, 1, 1
  20. Li, 1999, Induction of low density lipoprotein receptor (LDLR) transcription by oncostatin M is mediated by the extracellular signal-regulated kinase signaling pathway and the repeat 3 element of the LDLR promoter., J. Biol. Chem., 274, 6747, 10.1074/jbc.274.10.6747 · DOI
  21. Yadav, 2005, Berberine, a strong polyriboadenylic acid binding plant alkaloid: spectroscopic, viscometric, and thermodynamic study., Bioorg. Med. Chem., 13, 165, 10.1016/j.bmc.2004.09.045 · DOI
  22. Okazaki, 2005, Identification of unique lipoprotein subclasses for visceral obesity by component profile in high-performance liquid chromatography., Arterioscler. Thromb. Vasc. Biol., 25, 578, 10.1161/01.ATV.0000155017.60171.88 · DOI
  23. Scazzocchio, 1998, Antimicrobial activity of Hydrastis canadensis extract and its major isolated alkaloids., Fitoterapia., 69, 58
  24. Weber, 2003, Chemical comparison of goldenseal (Hydrastis canadensis L.) root powder from three commercial suppliers., J. Agric. Food Chem., 51, 7352, 10.1021/jf034339r · DOI
  25. Weber, 2003, Method validation for determination of alkaloid content in goldenseal root powder., J. AOAC Int., 86, 476, 10.1093/jaoac/86.3.476 · DOI
  26. Betz, J., S. M. Musser, and G. M. Larkin. 1998. Differentiation between goldenseal (Hydrastis canadensis L.) and possible adulterants by LC/MS. In Proceedings of the 39th Annual Meeting of the American Society of Pharmacognosy. Glendale, AZ: American Society of Pharmacognosy. p. 129.
  27. Liu, 2000, Identification of a novel sterol-independent regulatory element in the human low density lipoprotein receptor promoter., J. Biol. Chem., 275, 5214, 10.1074/jbc.275.7.5214 · DOI · Paper page
  28. Grand-Perret, 2001, SCAP ligands are potent new lipid-lowering drugs., Nat. Med., 7, 1332, 10.1038/nm1201-1332 · DOI · Paper page
  29. Liu, 2003, Synergistic activation of human LDL receptor expression by SCAP ligand and cytokine oncostatin M., Arterioscler. Thromb. Vasc. Biol., 23, 90, 10.1161/01.ATV.0000046229.77566.E5 · DOI
  30. Li, 2001, Determination of the major isosteroidal alkaloids in bulbs of Fritillaria by high-performance liquid chromatography coupled with evaporative light scattering detection., J. Chromatogr. A., 909, 207, 10.1016/S0021-9673(00)01083-9 · DOI
  31. Hsieh, 1998, Bacteria lacking a multidrug pump: a sensitive tool for drug discovery., Proc. Natl. Acad. Sci. USA., 95, 6602, 10.1073/pnas.95.12.6602 · DOI
  32. Stermitz, 2000, Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor., Proc. Natl. Acad. Sci. USA., 97, 1433, 10.1073/pnas.030540597 · DOI
  33. Samosorn, 2006, Synthesis of functionalised 2-aryl-5-nitro-1H-indoles and their activity as bacterial NorA efflux pump inhibitors., Bioorg. Med. Chem., 14, 857, 10.1016/j.bmc.2005.09.019 · DOI
  34. Taub, 2005, Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration of P-gp activity., Drug Metab. Dispos., 33, 1679, 10.1124/dmd.105.005421 · DOI
  35. Stierle, 2005, Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs., Biochem. Pharmacol., 70, 1424, 10.1016/j.bcp.2005.08.007 · DOI
  36. Constable, 2006, P-glycoprotein expression in human retinal pigment epithelium cell lines., Exp. Eye Res., 83, 24, 10.1016/j.exer.2005.10.029 · DOI
  37. Minderman, 1996, DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux., Cytometry., 25, 14, 10.1002/(SICI)1097-0320(19960901)25:1<14::AID-CYTO2>3.0.CO;2-E · DOI
  38. Spady, 1988, Interaction of dietary cholesterol and triglyceride in the regulation of hepatic low density lipoprotein transport in the hamster., J. Clin. Invest., 81, 300, 10.1172/JCI113321 · DOI
  39. Bensch, 1999, Effects of LY295427, a low-density lipoprotein (LDL) receptor up-regulator, on LDL receptor gene transcription and cholesterol metabolism in normal and hypercholesterolemic hamsters., J. Pharmacol. Exp. Ther., 289, 85, 10.1016/S0022-3565(24)38110-8 · DOI
  40. Lloyd, 1908, Drugs and medicines of North America: Hydrastis canadensis., Bull. Lloyd Library Bot. Pharm. Materia Med., 10, 76
  41. Qin, 2006, Synthesis, DNA-binding affinities, and binding mode of berberine dimers., Bioorg. Med. Chem., 14, 25, 10.1016/j.bmc.2005.07.069 · DOI
  42. Brusq, 2006, Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine., J. Lipid Res., 47, 1281, 10.1194/jlr.M600020-JLR200 · DOI

Cited by

Sorted by citations

Metadata

Authors
Abidi, P., Chen, W., Kraemer, F. B., Li, H., & Liu, J.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2006-10
Volume
47
Issue
10
Pages
2134-2147
ISSN
0022-2275
DOI
10.1194/jlr.m600195-jlr200
Cited by
43
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review